For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a significant change. These groundbreaking therapies protect the transthyretin protein, preventing its harmful build-up and alleviating the severity of the disease . People are now reporting benefits in